Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablynx Adds Sanofi To Its List Of Big Pharma Partners

Executive Summary

Sanofi is the latest big pharma, following on from Merck & Co., AbbVie and others, to team up with Belgian Nanobody drug developer Ablynx.

You may also be interested in...



Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign

Sanofi's €3.9bn acquisition of Ablynx will allow the French big pharma to build up its rare blood disorder pipeline and bring in complementary programs in areas like respiratory infections.

Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition

Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.

Ablynx Ups Profile Stateside With $200m Nasdaq Listing

Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel